602 related articles for article (PubMed ID: 34990237)
1. CAR T cells produced in vivo to treat cardiac injury.
Rurik JG; Tombácz I; Yadegari A; Méndez Fernández PO; Shewale SV; Li L; Kimura T; Soliman OY; Papp TE; Tam YK; Mui BL; Albelda SM; Puré E; June CH; Aghajanian H; Weissman D; Parhiz H; Epstein JA
Science; 2022 Jan; 375(6576):91-96. PubMed ID: 34990237
[TBL] [Abstract][Full Text] [Related]
2. 2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies.
Xu Y; Liu Q; Zhong M; Wang Z; Chen Z; Zhang Y; Xing H; Tian Z; Tang K; Liao X; Rao Q; Wang M; Wang J
J Hematol Oncol; 2019 May; 12(1):49. PubMed ID: 31097020
[TBL] [Abstract][Full Text] [Related]
3. Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering.
Billingsley MM; Singh N; Ravikumar P; Zhang R; June CH; Mitchell MJ
Nano Lett; 2020 Mar; 20(3):1578-1589. PubMed ID: 31951421
[TBL] [Abstract][Full Text] [Related]
4. Purification of mRNA Encoding Chimeric Antigen Receptor Is Critical for Generation of a Robust T-Cell Response.
Foster JB; Choudhari N; Perazzelli J; Storm J; Hofmann TJ; Jain P; Storm PB; Pardi N; Weissman D; Waanders AJ; Grupp SA; Karikó K; Resnick AC; Barrett DM
Hum Gene Ther; 2019 Feb; 30(2):168-178. PubMed ID: 30024272
[TBL] [Abstract][Full Text] [Related]
5. Generation of CAR-T Cells for Cancer Immunotherapy.
Xu Q; Harto H; Berahovich R; Xu S; Zhou H; Golubovskaya V; Wu L
Methods Mol Biol; 2019; 1884():349-360. PubMed ID: 30465215
[TBL] [Abstract][Full Text] [Related]
6. [Application of mRNA nano-delivery system in CAR-T tumor immunotherapy].
Zeng Y; Wei S; Sun J; Xu N
Sheng Wu Gong Cheng Xue Bao; 2024 May; 40(5):1338-1351. PubMed ID: 38783801
[TBL] [Abstract][Full Text] [Related]
7. In Vitro Engineering Chimeric Antigen Receptor Macrophages and T Cells by Lipid Nanoparticle-Mediated mRNA Delivery.
Ye Z; Chen J; Zhao X; Li Y; Harmon J; Huang C; Chen J; Xu Q
ACS Biomater Sci Eng; 2022 Feb; 8(2):722-733. PubMed ID: 35104103
[TBL] [Abstract][Full Text] [Related]
8. Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies.
Mamonkin M; Mukherjee M; Srinivasan M; Sharma S; Gomes-Silva D; Mo F; Krenciute G; Orange JS; Brenner MK
Cancer Immunol Res; 2018 Jan; 6(1):47-58. PubMed ID: 29079655
[TBL] [Abstract][Full Text] [Related]
9. A Novel Siglec-4 Derived Spacer Improves the Functionality of CAR T Cells Against Membrane-Proximal Epitopes.
Schäfer D; Henze J; Pfeifer R; Schleicher A; Brauner J; Mockel-Tenbrinck N; Barth C; Gudert D; Al Rawashdeh W; Johnston ICD; Hardt O
Front Immunol; 2020; 11():1704. PubMed ID: 32849600
[TBL] [Abstract][Full Text] [Related]
10. Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients.
Xiao L; Cen D; Gan H; Sun Y; Huang N; Xiong H; Jin Q; Su L; Liu X; Wang K; Yan G; Dong T; Wu S; Zhou P; Zhang J; Liang W; Ren J; Teng Y; Chen C; Xu XH
Mol Ther; 2019 Jun; 27(6):1114-1125. PubMed ID: 30962163
[TBL] [Abstract][Full Text] [Related]
11. Fighting Cardiac Fibrosis with CAR T Cells.
Friedman SL
N Engl J Med; 2022 Apr; 386(16):1576-1578. PubMed ID: 35443114
[No Abstract] [Full Text] [Related]
12. In Vitro-Transcribed (IVT)-mRNA CAR Therapy Development.
Miliotou AN; Papadopoulou LC
Methods Mol Biol; 2020; 2086():87-117. PubMed ID: 31707670
[TBL] [Abstract][Full Text] [Related]
13. In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update.
Soundara Rajan T; Gugliandolo A; Bramanti P; Mazzon E
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899932
[TBL] [Abstract][Full Text] [Related]
14. The rational development of CD5-targeting biepitopic CARs with fully human heavy-chain-only antigen recognition domains.
Dai Z; Mu W; Zhao Y; Jia X; Liu J; Wei Q; Tan T; Zhou J
Mol Ther; 2021 Sep; 29(9):2707-2722. PubMed ID: 34274536
[TBL] [Abstract][Full Text] [Related]
15. Automated Manufacture of Autologous CD19 CAR-T Cells for Treatment of Non-hodgkin Lymphoma.
Jackson Z; Roe A; Sharma AA; Lopes FBTP; Talla A; Kleinsorge-Block S; Zamborsky K; Schiavone J; Manjappa S; Schauner R; Lee G; Liu R; Caimi PF; Xiong Y; Krueger W; Worden A; Kadan M; Schneider D; Orentas R; Dropulic B; Sekaly RP; de Lima M; Wald DN; Reese JS
Front Immunol; 2020; 11():1941. PubMed ID: 32849651
[TBL] [Abstract][Full Text] [Related]
16. Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice.
Li D; Li N; Zhang YF; Fu H; Feng M; Schneider D; Su L; Wu X; Zhou J; Mackay S; Kramer J; Duan Z; Yang H; Kolluri A; Hummer AM; Torres MB; Zhu H; Hall MD; Luo X; Chen J; Wang Q; Abate-Daga D; Dropulic B; Hewitt SM; Orentas RJ; Greten TF; Ho M
Gastroenterology; 2020 Jun; 158(8):2250-2265.e20. PubMed ID: 32060001
[TBL] [Abstract][Full Text] [Related]
17. Research advance in lipid nanoparticle-mRNA delivery system and its application in CAR-T cell therapy.
Ye B; Hu Y; Zhang M; Huang H
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 51(2):185-191. PubMed ID: 36161298
[TBL] [Abstract][Full Text] [Related]
18. Lipid nanoparticles produce chimeric antigen receptor T cells with interleukin-6 knockdown in vivo.
Zhou JE; Sun L; Jia Y; Wang Z; Luo T; Tan J; Fang X; Zhu H; Wang J; Yu L; Yan Z
J Control Release; 2022 Oct; 350():298-307. PubMed ID: 36002054
[TBL] [Abstract][Full Text] [Related]
19. Treatment of Multiple Myeloma Using Chimeric Antigen Receptor T Cells with Dual Specificity.
Globerson Levin A; Rawet Slobodkin M; Waks T; Horn G; Ninio-Many L; Deshet Unger N; Ohayon Y; Suliman S; Cohen Y; Tartakovsky B; Naparstek E; Avivi I; Eshhar Z
Cancer Immunol Res; 2020 Dec; 8(12):1485-1495. PubMed ID: 33008840
[TBL] [Abstract][Full Text] [Related]
20. Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells.
Bai Z; Lundh S; Kim D; Woodhouse S; Barrett DM; Myers RM; Grupp SA; Maus MV; June CH; Camara PG; Melenhorst JJ; Fan R
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34006631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
